

DAFTAR PUSTAKA

1. Kikunaga K, Ishikura K, Terano C, Sato M, Komaki F, Hamasaki Y, et al. High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study). *Clin Exp Nephrol*. 2017;21(4):651–7.
2. Albar H. Tata laksana Sindrom Nefrotik Kelainan Minimal pada Anak. *Sari Pediatr*. 2016;8(1):60.
3. Reynolds BC, Oswald RJA. <p>Diagnostic and Management Challenges in Congenital Nephrotic Syndrome</p>. *Pediatr Heal Med Ther*. 2019;Volume 10:157–67.
4. Pardede SO. Podosit dan Slit Diafragma serta Perannya. *Sari Pediatr*. 2016;6(3):119.
5. Jalanko H. Congenital nephrotic syndrome. *Pediatr Nephrol*. 2009;24(11):2121–8.
6. Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. *Kidney Int Suppl* [Internet]. 2015;5(1):2–7. Available from: <http://dx.doi.org/10.1038/kisup.2015.2>
7. Stasinou SM, Valasoulis G, Georgiou I, Maria K, Paraskevaides E, Plachouras N. Congenital Nephrotic Syndrome of the Finnish Type: A Greek Case Report. *Health (Irvine Calif)*. 2014;06(12):1436–9.
8. Jones LV. Treatment of idiopathic nephrotic syndrome in children. *Bol Med Hosp Infant Mex*. 2014;71(5):315–22.
9. Hinkes BG, Mucha B, Vlangos CN, Gbadegesin R, Liu J, Hasselbacher K, et al. Nephrotic syndrome in the first year of life: Two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). *Pediatrics*. 2007;119(4).
10. Spahiu L, Merovci B, Jashari H, Këpuska AB, Rugova BE. Congenital Nephrotic Syndrome - Finish Type. *Med Arch (Sarajevo, Bosnia Herzegovina)*. 2016;70(3):232–4.
11. Lechner BL, Bockenhauer D, Iragorri S, Kennedy TL, Siegel NJ. The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. *Pediatr Nephrol*. 2004;19(7):744–8.
12. Pugh D, Gallacher PJ, Dhaun N. Management of Hypertension in Chronic Kidney Disease. *Drugs* [Internet]. 2019;79(4):365–79. Available from: <https://doi.org/10.1007/s40265-019-1064-1>
13. Benvenga S, Vita R, Di Bari F, Fallahi P, Antonelli A. Do Not Forget Nephrotic



Syndrome as a Cause of Increased Requirement of Levothyroxine Replacement Therapy.

Eur Thyroid J. 2015;4(2):138–42.

14. Toubiana J, Schlageter MH, Aoun B, Dunand O, Vitkevic R, Bensman A, et al. Therapy-resistant anaemia in congenital nephrotic syndrome of the Finnish type-implication of EPO, transferrin and transcobalamin losses. *Nephrol Dial Transplant*. 2009;24(4):1338–40.
15. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. *Clin Kidney J*. 2016;9(4):583–91.
16. Rocha LP, Custódio FB, Machado JR, de Morais Pereira LH, Monteiro MLG dos R, Laterza VL, et al. Diagnosis of congenital and infantile nephrotic syndromes in renal biopsies in Minas Gerais, Brazil: Six case reports. *Ultrastruct Pathol [Internet]*. 2016;40(6):311–6. Available from: <http://dx.doi.org/10.1080/01913123.2016.1221868>
17. Jain D, Aggarwal HK, Pavan Kumar YM, Jain P. Evaluation of thyroid dysfunction in patients with nephrotic syndrome. *Med Pharm Reports*. 2019;92(2):139–44.
18. Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J*. 2011;32(14):1769–818.
19. Harvey TW, Engel JE, Chade AR. Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism. *Am J Nephrol*. 2016;43(2):74–84.
20. Madani A, Umar SU, Taghaodi R, Hajizadeh N, Rabbani A, Z-Mehrjardi H. The effect of long-term steroid therapy on linear growth of nephrotic children. *Iran J Pediatr*. 2011;21(1):21–7.
21. Chen Y, Zhang Y, Wang F, Zhang H, Zhong X, Xiao H, et al. Analysis of 14 Patients With Congenital Nephrotic Syndrome. *Front Pediatr*. 2019;7(August):1–8.
22. Kumar M, Ghunawat J, Saikia D, Manchanda V. Incidence and risk factors for major infections in hospitalized children with nephrotic syndrome. *J Bras Nefrol*. 2019;41(4):526–33.
23. Hölttä T, Jalanko H. Hölttä-Jalanko2020_Article_CongenitalNephroticSyndromeIsE.pdf.2020;1985–90.
24. Bérody S, Heidet L, Gribouval O, Harambat J, Niaudet P, Baudouin V, et al. Treatment and outcome of congenital nephrotic syndrome. *Nephrol Dial Transplant*. 2019;34(3):458–67.



25. Anak P. Edisi kedua. 2012.
26. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. *Pediatr Clin Pract Guidel Policies*. 2021;1099–1099.
27. Boyer O, Schaefer F, Haffner D, Bockenbauer D, Hölttä T, Bérody S, et al. Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. *Nat Rev Nephrol*. 2021;17(4):277–89.
28. Adamczuk D, Roszkowska-Blaim M. Long-term outcomes in children with chronic kidney disease stage 5 over the last 40 years. *Arch Med Sci*. 2017;13(3):635–44.
29. Dufek S, Ylinen E, Trautmann A, Alpay H, Ariceta G, Aufricht C, et al. Infants with congenital nephrotic syndrome have comparable outcomes to infants with other renal diseases. *Pediatr Nephrol*. 2019;34(4):649–55.
30. Drube J, Wan M, Bonthuis M, Wühl E, Bacchetta J, Santos F, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. *Nat Rev Nephrol* [Internet]. 2019;15(9):577–89. Available from: <http://dx.doi.org/10.1038/s41581-019-0161-4>